DARENasdaqPharmaceutical PreparationsFiscal year ends December 31
Dare Bioscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.71−0.02 (-2.57%)
Close on Oct 19, 2026
- Market cap
- $10.51M
- P/E (TTM)
- –
- Dividend yield
- –
Dare Bioscience, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development services and royalty revenue | $187.55K | – | – | – | – | – | – | $41.69K | – | – | $7.89K | $0 | 100.0% | – |
| License | – | – | – | – | – | – | $9.78K | $0 | – | – | $0 | $1.00M | – | – |
| License And Collaboration Revenues | – | – | – | – | – | – | – | – | – | – | $0 | – | – | – |
| Royalty Revenue | – | – | – | – | – | – | – | – | – | $17.00K | – | – | – | – |
| License And Collaboration Revenue | – | – | – | $0 | $0 | $12.80M | – | $0 | $0 | $12.80M | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Dare Bioscience's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.